
    
      The main purpose of this study is to evaluate the efficacy of bemarituzumab (FPA144), which
      is a targeted antibody, in combination with modified FOLFOX6 compared to placebo in
      combination with modified FOLFOX6 in participants with Gastric Cancer as measured by overall
      survival.
    
  